- Home
- VET vs RCUS Comparison
VET vs RCUS Comparison
Compare VET & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VET
- RCUS
- Stock Information
- Founded
- VET 1994
- RCUS 2015
- Country
- VET Canada
- RCUS United States
- Employees
- VET N/A
- RCUS N/A
- Industry
- VET Oil & Gas Production
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- VET Energy
- RCUS Health Care
- Exchange
- VET Nasdaq
- RCUS Nasdaq
- Market Cap
- VET N/A
- RCUS 1.2B
- IPO Year
- VET N/A
- RCUS 2018
- Fundamental
- Price
- VET $8.10
- RCUS $7.86
- Analyst Decision
- VET
- RCUS Strong Buy
- Analyst Count
- VET 0
- RCUS 10
- Target Price
- VET N/A
- RCUS $29.50
- AVG Volume (30 Days)
- VET 1.3M
- RCUS 872.5K
- Earning Date
- VET 03-05-2025
- RCUS 05-07-2025
- Dividend Yield
- VET 4.34%
- RCUS N/A
- EPS Growth
- VET N/A
- RCUS N/A
- EPS
- VET N/A
- RCUS N/A
- Revenue
- VET $1,253,410,386.00
- RCUS $258,000,000.00
- Revenue This Year
- VET $29.31
- RCUS N/A
- Revenue Next Year
- VET $2.74
- RCUS $28.07
- P/E Ratio
- VET N/A
- RCUS N/A
- Revenue Growth
- VET N/A
- RCUS 120.51
- 52 Week Low
- VET $7.09
- RCUS $7.56
- 52 Week High
- VET $12.79
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- VET 45.94
- RCUS 27.90
- Support Level
- VET $7.43
- RCUS $8.02
- Resistance Level
- VET $8.48
- RCUS $8.57
- Average True Range (ATR)
- VET 0.25
- RCUS 0.44
- MACD
- VET 0.08
- RCUS -0.01
- Stochastic Oscillator
- VET 63.33
- RCUS 12.19
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.